Hunter Capital (HUNTER) Q4 2024 earnings summary

Executive summary

• Focuses on investments in technology and life science, supporting growth and preparing portfolio companies for exit via IPO or sale.

• Achieved a stable financial position with low debt and strong liquidity by year-end 2024.

• Market value of securities holdings at year-end was approximately 47.2 MSEK, with cash holdings of 6.2 MSEK.

Financial highlights

• Net sales for Q4 2024 were -173 TSEK, down from 272 TSEK in Q4 2023; full-year net sales were 1.04 MSEK, up from 745 TSEK.

• EBITDA for Q4 2024 was -929 TSEK (vs. -484 TSEK); full-year EBITDA was -907 TSEK (vs. -786 TSEK).

• Result after financial items for Q4 2024 was 636 TSEK (vs. -491 TSEK); full-year result was 8.25 MSEK (vs. -706 TSEK).

• Earnings per share for Q4 2024 was 0.14 SEK (vs. -0.01 SEK); full-year EPS was 1.82 SEK (vs. -0.02 SEK).

• Cash and cash equivalents at year-end were 6.21 MSEK (vs. 0 SEK); equity was 32.05 MSEK (vs. 5.05 MSEK).

Outlook and guidance

• Actively seeking new investment opportunities, with recent participation in SynAct Pharma's directed share issue.

• No need for new credit in the near term due to low debt and strong liquidity.

• No dividend proposed for the 2024 financial year.